<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02985372</url>
  </required_header>
  <id_info>
    <org_study_id>ESDCLDC in NDEAML</org_study_id>
    <nct_id>NCT02985372</nct_id>
  </id_info>
  <brief_title>Decitabine in Combination With Low-dose Cytarabine in Elderly Patients With Acute Myeloid Leukemia</brief_title>
  <official_title>Efficacy and Safety of Decitabine in Combination With Low-dose Cytarabine as Inductive Treatment in Newly Diagnosed Elderly Patients With Acute Myeloid Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chunyan Ji</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Binzhou Medical University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shengli Oilfield Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Heze Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Military Genaral Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jinan Central Hospital Affiliated to Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jining Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Linyi People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qingdao University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>People's Hospital of Rizhao</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Qianfoshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University (Qingdao)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taian City Central Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated hospital of Taishan medical university</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Weihai Municipal Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Affiliated Hospital of Weifang Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zibo First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central Hospital of Zibo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Shandong University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This prospective multicenter clinical study was designed to assess the efficacy and safety of
      decitabine in combination with low-dose cytarabine induction treatment for elderly patients
      with newly diagnosed acute myeloid leukemia (AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5
      consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days
      (day 4-13).

      Hydroxyurea was permitted as rescue medication if white blood count (WBC) was &gt;20×109/L and
      but was discontinued at least 24h before decitabine treatment.

      Supportive care including blood product transfusions, G-CSF, antiemetic medications,
      antiviral and antifungal medications, or empiric antibiotics may be used at the clinical
      discretion of the investigator.

      Curative effect was evaluated after two cycles:

        1. &lt;5% blast in the marrow, enter into maintenance therapy (Group A)

        2. ≥5% blast in the marrow, continue induction therapy two cycles,

           ① &lt;5% blast in the marrow, enter into maintenance therapy (Group B);

           ② ≥5% blast in the marrow, dropped out of the study (Group C)

        3. marrow blast decline &lt;60%, dropped out of the study (Group C).

      Maintenance therapy regimen:

        1. Ara-C 1g/m2/d iv drip d1-4 1 cycle

        2. DEC 15mg/m2/d iv drip d1-5 1 cycle

        3. Ara-C 1g/m2/d iv drip d1-4 1 cycle

        4. DEC 15mg/m2/d iv drip d1-5 1 cycle
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>complete remission rate</measure>
    <time_frame>three years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality rate</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>recurrence rate</measure>
    <time_frame>three years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acute Myeloid Leukemia, Adult</condition>
  <arm_group>
    <arm_group_label>Acute myeloid leukemia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Decitabine</intervention_name>
    <description>All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).</description>
    <arm_group_label>Acute myeloid leukemia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cytarabine</intervention_name>
    <arm_group_label>Acute myeloid leukemia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with previously untreated non-M3 AML (diagnosed by the WHO2016 criteria).

          2. Age: ≥ 60 and ≤ 75 years.

          3. Eastern Cooperative Oncology Group (ECOG) performance status 0-2.

          4. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT)≤2.5x upper limit
             of normal (ULN), total bilirubin ≤ 1.5 ULN, serum creatinine &lt; 2ULN.

          5. Without central nervous system symptoms.

          6. Willing to accept the follow-up.

          7. Normal heart function(EF&gt;50%). The subjects volunteer to sign the informed consent.

        Exclusion Criteria:

          1. With severe cardiac, renal or hepatic insufficiency.

          2. With other cancers requiring treatment.

          3. With other hematological diseases(e.g. Hemophilia, myelofibrosis, etc.).

          4. With severe infection or metabolic disease(including tuberculosis and pulmonary
             aspergillosis).

          5. Brain disorders or severe mental diseases which could limit compliance with study
             requirements.

          6. Major operation within 3 weeks.

          7. With HIV infection or AIDS-associated diseases.

          8. Any drug abuse, medical, mental or social situations which would affect the results.

          9. Hypersensitivity to cytarabine (not including drug fever or exanthema) or decitabine.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Chunyan Ji, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>Shandong University</affiliation>
  </overall_official>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 25, 2016</study_first_submitted>
  <study_first_submitted_qc>December 3, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2016</study_first_posted>
  <last_update_submitted>December 3, 2016</last_update_submitted>
  <last_update_submitted_qc>December 3, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 7, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Shandong University</investigator_affiliation>
    <investigator_full_name>Chunyan Ji</investigator_full_name>
    <investigator_title>professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytarabine</mesh_term>
    <mesh_term>Decitabine</mesh_term>
    <mesh_term>Azacitidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

